Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine - LARVOL DELTA

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

MVA-CMDR boost vaccination reprograms monocyte subsets toward a less inflammatory profile in PHIV: results from the RVF534 clinical trial (AIDS 2026) - "Longitudinal analyses evaluated the impact of DNA/MVA-CMDR prime-boost within a therapeutic vaccination schedule, with or without Cervarix (n=20), compared to a control group receiving Cervarix alone (n=5)... The HIVIS DNA/MVA-CMDR prime-boost redistributed MO subsets toward a less inflammatory profile. Stratification by baseline inflammation revealed impaired functionality in the high-inflammatory group, which resolved by the end of vaccination. Ongoing analyses of monocyte trained immunity are expected to clarify the mechanisms underlying this functional reprogramming."

Clinical • Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD14 • IL6 • TNFA

Human Papillomavirus (HPV)-The Interplay between Vaginal Microbiota and HPV, along with its Prevention. (PubMed, Curr HIV Res) - "The relationship between the vaginal microbiome and HPV shows that preventive strategies such as probiotics and vaccination may significantly reduce infection risk and cancer progression."

Journal • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (clinicaltrials.gov) - P4 | N=5000 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: May 2026 ➔ Dec 2026 | Trial primary completion date: May 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls. (PubMed, Vaccine) - P3 | "Whilst some effect of malaria on antibody responses was observed in the two-dose arms, these were mostly small in magnitude and unlikely to have clinical significance. Single-dose arms results are reassuring but further evaluations in larger populations would be valuable to confirm the findings. The potential for an effect of moderate or severe infection with greater parasite burden remains unclear. (NCT02834637)."

Journal • Cervical Cancer • Human Immunodeficiency Virus • Infectious Disease • Malaria • Oncology • Solid Tumor

Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study. (PubMed, Hum Vaccin Immunother) - P4 | "The objective of the study is to monitor AS04-adjuvanted HPV-16/18 vaccine (Cervarix, GSK) safety in a real-world setting in China, using electronic health records from the Yinzhou Regional Health Information Platform (YRHIP)...Further research is needed to address residual confounding factors and validate findings. The overall safety profile of AS04-adjuvanted HPV-16/18 vaccination in Chinese girls and women aged 9-45 y could be considered as favorable.Clinical Trial Registration:Retrospectively registered on http://www.chinadrugtrials.org.cn/index.html, 22 March 2021, registration number CTR20210523."

Journal • Observational data • Retrospective data • Cervical Cancer • Human Papillomavirus Infection • Immunology • Infectious Disease • Oncology • Sarcoidosis • Solid Tumor

Cost-effectiveness of human papillomavirus vaccination in Jordan: A modelling study. (PubMed, Vaccine) - "A single dose of Cecolin® could prevent more than half of the expected lifetime cervical cancer cases and deaths in Jordan and is very likely to be cost saving. Cervarix™ may be more impactful than Cecolin® but this depends on cross-protection assumptions. Continued multi-sectoral engagement and donor collaboration will be essential to ensure sustainable integration into the national immunization programme."

HEOR • Journal • Cervical Cancer • Oncology • Solid Tumor

Human papillomavirus: role of HPV2 and HPV9 in reducing the burden of cervical cancer in sub-Saharan Africa. (PubMed, Int J Infect Dis) - "Prophylactic HPV vaccines, notably Cervarix® (bivalent) and Gardasil 9® (nonavalent), have profoundly transformed primary prevention of cervical cancer. Integrating vaccination into school curricula, strengthening cold chains, and combating misinformation are essential levers for increasing vaccination coverage. A coordinated strategy between governments, international partners, and local communities is indispensable to achieving the WHO's goal of eliminating cervical cancer by 2030."

Journal • Review • Cervical Cancer • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience. (PubMed, Pathophysiology) - "Furthermore, the hypothesis implicating a pathogenic role for aluminum adjuvants was unsupported by experimental evidence; HANS animal models were flawed methodologically and unreproducible experimentally. In summary, we believe that implementing worldwide HPV vaccination strategies, including gender-neutral and single-dose programs, as well as denouncing pseudoscientific claims hold the potential to eliminate high-risk HPV types globally."

Journal • Cervical Cancer • Immunology • Infectious Disease • Measles • Oncology • Solid Tumor

Global trends and forecasts of cervical cancer and a real-world safety assessment of human papillomavirus vaccines in women: A systematic analysis of the Global Burden of Disease study 2021 and the Vaccine Adverse Event Reporting System database. (PubMed, PLoS One) - "Despite declining age-standardized rates, CCA continues to impose a substantial global burden with marked regional disparities. Sustained HPV vaccine prevention efforts should be supported by epidemiological evidence and transparent, evidence-based safety communication."

Adverse events • HEOR • Journal • Real-world evidence • Retrospective data • Cervical Cancer • Oncology • Solid Tumor

Maximizing impact: the power of early HPV vaccination for long-term protection-lessons from a systematic review and meta-regression analysis. (PubMed, J Public Health (Oxf)) - "HPV16/18-AS04 vaccine provides long-term protection against cervical premalignant lesions and cervical cancer in both controlled and real-world settings, particularly when administered at younger ages. The evidence urges policymakers and the community to ensure HPV vaccination begins at the youngest recommended ages."

Journal • Cervical Cancer • Gynecology • Oncology • Solid Tumor

HLA-A*11:01-restricted HPV16/18 E6/E7 peptides with stable MHC binding identify prophylactic and therapeutic CD8+ T cell vaccine candidates for Asian populations (ESMO-IO 2025) - "Background Cervical cancer largely caused by high-risk HPV strains accounts for over 170000 deaths annually despite advances in preventive vaccines (e.g Gardasil-9 and Cervarix). 2 in silico hits (1 HPV18 E6 and 1 HPV18 E7) did not bind stably to soluble HLA-A*11:01. Work is ongoing to validate functional immunogenicity of these 15 peptides.Conclusions In silico predictions and in vitro binding assay identified 15 E6/E7 epitopes from HPV16/18, laying the foundation for prophylactic and therapeutic cancer vaccine development in HLA-A*11:01-prevalent populations."

Clinical • Cervical Cancer • Oncology • Solid Tumor • CD8 • IFNG • TNFA

Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial. (PubMed, NPJ Vaccines) - "Prophylactic human papillomavirus vaccines such as Cervarix® and Gardasil®9 induce robust and sustained antibody responses over time...By Month 36, MBC responses to both vaccines for both HPV16 and 18 were similar across all dosing arms. The clinical significance of the dose response remains to be evaluated; however, the presence of MBCs in the circulation after 3 years with a single vaccine dose is encouraging in terms of generating long-lasting protection with a one-dose vaccination strategy."

Journal • Oncology

Cost-effectiveness of HPV catch-up vaccination program in women aged 13-24 years in a middle income country. (PubMed, J Gynecol Oncol) - "All catch-up vaccination programs for women aged 13 to 24 years produce additional health benefits and reduce healthcare costs. Vaccination with 9vHPV was considered the most cost-effective option."

HEOR • Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Chlamydia trachomatis Infection and Its Association with Human Papillomavirus Among Adolescent Girls and Young Women of Eastern Cape, South Africa. (PubMed, Epidemiologia (Basel)) - "There was a high burden of C. trachomatis and HPV coinfection. C. trachomatis coinfection influenced HPV genotype prevalence and distribution, including those that are targeted by the current commercial HPV vaccines, suggesting that the high burden of C. trachomatis among AGYW may pose challenges to the ongoing HPV vaccination program. Integrated STI screening and prevention strategies are needed in rural South African settings."

Journal • Infectious Disease • Oncology

Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "The evidence in this network meta-analysis of HPV vaccines is based on extensive searches and analyses. There is evidence from randomised controlled trials that HPV vaccination reduces the risk of pre-cancerous outcomes such as CIN2+ and anogenital warts. No data were available for cervical cancer or other cancer outcomes, and no data on pre-cancer outcomes were available for vaccination under age 15 years. There were no safety concerns noted in the studies."

Clinical • Journal • Retrospective data • Review • Cervical Cancer • Dermatology • Human Papillomavirus Infection • Infectious Disease • Oncology • Penile Cancer • Solid Tumor

VERY HIGH PREVALENCE OF HIGH-RISK HPV AMONGST ADOLESCENT GIRLS AND YOUNG WOMEN IN A HIGH HIV BURDEN RURAL AREA OF SOUTH AFRICA (IPVC 2025) - "South Africa introduced national HPV vaccination for Grade 4 girls (age ≥9) in 2014, with the bivalent vaccine Cervarix®... HPV, including HR HPV, was extremely common in AGYW in rural South Africa. There is an urgent need to roll out the 9-valent vaccine and ensure that cervical screening programmes are effectively implemented, particularly for women living with HIV."

Clinical • Cervical Cancer • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

HUMAN PAPILLOMAVIRUS VACCINE LANDSCAPE (IPVC 2025) - " Since 2006, WHO has approved five HPV vaccines: three bivalent vaccines (Cervarix, Cecolin, and Walrinvax); one quadrivalent vaccine (Gardasil); and one nonavalent vaccine (Gardasil 9). Two domestically licensed vaccines are available in Bangladesh (HPvax) and India (Cervavac)... Global vaccine introduction has made good progress in recent years. Countries that have introduced the vaccine subnationally—such as China, Russia, and India—have large populations and wide geographical areas. The vaccine landscape in China is changing rapidly with more low-cost vaccines becoming available, that will likely further influence global vaccine availability."

Cervical Cancer • Genito-urinary Cancer • Penile Cancer • Solid Tumor

GLOBE-HPV: HPV VACCINE COVERAGE AMONG ADOLESCENT GIRLS FOLLOWING A NATIONAL VACCINATION PROGRAM: A COMMUNITY-BASED CROSS-SECTIONAL STUDY IN BANGLADESH (IPVC 2025) - "The campaign targeted girls studying in grades V to IX or those out-of-school aged 10-14 years, with a single dose of the bivalent vaccine (Cervarix®, GSK)... Our findings indicate lower HPV vaccination coverage in the study areas compared to national coverage (88.9%) following completion of all phases of the campaign. Significant disparities in coverage were observed between girls living in an urban slum and those living in a rural area. These findings highlight the urgent need for targeted strategies to improve awareness, address vaccine hesitancy, and strengthen age-specific community outreach efforts for out-of-school girls."

Observational data

ACTIVELY PROMOTE THE VACCINATION OF HUMAN PAPILLOMAVIRUS VACCINE IN CHINA (IPVC 2025) - " At present, there are 5 HPV vaccines in China, including bivalent vaccine (Cervarix, Cecolin and Wozehui), 4-valent and 9-valent vaccine (Gardasil 4 and 9), for women aged 9 to 45 ys,and for men aged 9 to 26y (4-valent), and 16 to 26ys(9-valent ). Now we have face big challenges to eliminate cervical cancer, With the combination of HPV vaccination and cervical cancer screening, China is accelerating the elimination of cervical cancer."

Cervical Cancer • Infectious Disease • Solid Tumor

HPV VACCINE EFFECTIVENESS AGAINST CERVICAL CANCER AND PRECANCER IN JAPAN: A TEST-NEGATIVE CASE–CONTROL STUDY (IPVC 2025) - "Introduction: Japan's human papillomavirus (HPV) immunization program for girls aged 12-16 years started in 2010 with the 2-valent vaccine (Cervarix). The 4-valent vaccine (Gardasil) was next introduced to the immunization program in 2011, while the 9-valent vaccine (Gardasil 9) was just recently introduced in 2023... These results indicate the real-world effectiveness of the 2- or 4-valent HPV vaccines after the introduction of the national immunization program in Japan."

Clinical • Cervical Cancer • Gynecology • Oncology • Solid Tumor

HPV VACCINE IN CHINA: PROGRESS AND CHALLENGES TOWARD THE NATIONAL IMMUNIZATION PROGRAM (IPVC 2025) - " At present, five HPV vaccines are commercially available in China, including three bivalent vaccines (Cervarix, Cecolin, and Walrinvax), one quadrivalent vaccine (Gardasil), and one nonavalent vaccine (Gardasil-9). Despite the increasing availability of HPV vaccines in China and the gradual expansion of provincial-level vaccination programs, national coverage remains critically low, particularly among the target age group of 9–14 years. Accelerating the integration of HPV vaccination into the national program, alongside strategies to improve affordability, accessibility, and public awareness, will be essential for China to close the gap with global progress and to advance toward cervical cancer elimination."

Cervical Cancer • Solid Tumor

Effects of Chronic S. mansoni Infection on Innate and Adaptive Immune Responses in Olive Baboons Vaccinated with Human Papillomavirus Vaccine (ASTMH 2025) - "Baboons were assigned to three groups: (1) untreated S. mansoni-infected, (2) S. mansoni-infected and treated with Praziquantel, and (3) uninfected controls. All received two doses of the Cervarix HPV vaccine four weeks apart...These findings emphasize the importance of a booster dose for enhanced antibody production and suggest that a delayed HPV-specific whole IgG response in untreated S. mansoni-infected individuals reinforces the need for booster HPV vaccination in endemic regions. The results affirm the vaccine's effectiveness in S. mansoni endemic areas."

Infectious Disease

Human Papillomavirus Vaccine immune responses in an Olive baboon model is not compromised by chronic Schistosoma mansoni infections. (PubMed, AIMS Microbiol) - "Baboons were assigned to three groups: (1) untreated S. mansoni-infected, (2) S. mansoni-infected and treated with Praziquantel, and (3) uninfected controls. All received two doses of the Cervarix HPV vaccine four weeks apart...Gardasil® quadrivalent HPV vaccine antigen was used in both ELISA and PBMC stimulation for cytokine ELISA supernatants...These findings emphasize the importance of a booster dose for strong antibody production and suggest that a delayed HPV-specific whole IgG response in untreated S. mansoni-infected individuals reinforces the need for booster HPV vaccination in endemic regions. The results affirm the vaccine's effectiveness in S. mansoni endemic areas."

Journal • Infectious Disease • Oncology

The Rehabilitation of a Patient with Acute Transverse Myelitis After HPV Vaccination-A Case Report. (PubMed, Diseases) - "We present a case of a 21-year-old woman who developed ATM two weeks following administration of the first dose of the HPV vaccine (Cervarix)...Although no causal link between HPV vaccination and ATM has been established, this case emphasizes the importance of considering post-vaccinal autoimmune phenomena. More importantly, it illustrates the critical role of early, targeted rehabilitation-particularly pelvic floor re-education and neuromodulation-in improving outcomes in patients with significant motor and autonomic deficits."

Journal • CNS Disorders • Immunology • Oncology